JP7108018B2 - 急性肺傷害を処置または予防する化合物、組成物および方法 - Google Patents

急性肺傷害を処置または予防する化合物、組成物および方法 Download PDF

Info

Publication number
JP7108018B2
JP7108018B2 JP2020506132A JP2020506132A JP7108018B2 JP 7108018 B2 JP7108018 B2 JP 7108018B2 JP 2020506132 A JP2020506132 A JP 2020506132A JP 2020506132 A JP2020506132 A JP 2020506132A JP 7108018 B2 JP7108018 B2 JP 7108018B2
Authority
JP
Japan
Prior art keywords
pazopanib
subject
pharmaceutical composition
day
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020506132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516689A5 (enExample
JP2020516689A (ja
Inventor
ディエンキン ウー
チャンイン ユアン
アブドゥル バシット
ウェンウェン タン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2020516689A publication Critical patent/JP2020516689A/ja
Publication of JP2020516689A5 publication Critical patent/JP2020516689A5/ja
Application granted granted Critical
Publication of JP7108018B2 publication Critical patent/JP7108018B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020506132A 2017-04-17 2018-04-17 急性肺傷害を処置または予防する化合物、組成物および方法 Active JP7108018B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762486232P 2017-04-17 2017-04-17
US62/486,232 2017-04-17
PCT/US2018/027980 WO2018195084A1 (en) 2017-04-17 2018-04-17 Compounds, compositions and methods of treating or preventing acute lung injury

Publications (3)

Publication Number Publication Date
JP2020516689A JP2020516689A (ja) 2020-06-11
JP2020516689A5 JP2020516689A5 (enExample) 2021-05-06
JP7108018B2 true JP7108018B2 (ja) 2022-07-27

Family

ID=63856399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020506132A Active JP7108018B2 (ja) 2017-04-17 2018-04-17 急性肺傷害を処置または予防する化合物、組成物および方法

Country Status (7)

Country Link
US (3) US11166953B2 (enExample)
EP (1) EP3612184B1 (enExample)
JP (1) JP7108018B2 (enExample)
CN (1) CN110753546B (enExample)
CA (1) CA3060247A1 (enExample)
IL (1) IL270070B2 (enExample)
WO (1) WO2018195084A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020386436A1 (en) * 2019-11-20 2022-05-26 Yale University Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
US20230181582A1 (en) * 2020-05-22 2023-06-15 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with viral infections
CN113624978B (zh) * 2021-04-06 2023-09-19 四川大学华西医院 通过检测肺泡灌洗液及血清白蛋白来评估急性呼吸窘迫综合征/急性肺损伤及预后的试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014503500A (ja) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
JP2014534215A (ja) 2011-10-31 2014-12-18 グラクソスミスクライン インテレクチュアル プロパティ リミテッド パゾパニブ製剤

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
JPH07507059A (ja) 1992-03-25 1995-08-03 デポムド　システムズ，インコーポレイテッド アルキル置換セルロースをベースとする持続放出性経口薬剤投与剤形
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
AU781718B2 (en) 1999-11-02 2005-06-09 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
EP1343782B1 (en) 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
EP1401423A4 (en) 2001-05-29 2006-08-16 Depomed Dev Ltd METHOD FOR THE TREATMENT OF GASTROÖSOPHAGEAL REFLUX DISEASE AND NURSING ACID BREAKDOWN
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7413751B2 (en) 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2008080153A2 (en) * 2006-12-22 2008-07-03 The Children's Hospital Of Philadelphia A novel protein kinase c therapy for the treatment of acute lung injury
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
EP2259844A4 (en) 2008-03-05 2012-02-01 Vicus Therapeutics Llc COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGICAL THERAPIES
US20120107304A1 (en) * 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
MY181439A (en) * 2011-02-28 2020-12-22 Sunshine Lake Pharma Co Ltd Substituted quinoline compounds and methods of use
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
EP3052480B1 (en) * 2013-09-30 2020-11-11 The Texas A & M University System Compositions associated with and methods of managing neutrophil movement
KR101636563B1 (ko) * 2014-01-24 2016-07-06 주식회사 엘지생명과학 급성 폐 손상 및 급성 호흡곤란 증후군의 예방 또는 치료용 조성물
US9718841B2 (en) * 2014-04-22 2017-08-01 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014503500A (ja) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
JP2014534215A (ja) 2011-10-31 2014-12-18 グラクソスミスクライン インテレクチュアル プロパティ リミテッド パゾパニブ製剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ahmad S，Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors，J Biomol Screen，2013年，18巻4号，388-399
Kim IK，Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery，Crit Care，2013年，17巻3号，R114
Kim S，ERK5 inhibition ameliorates pulmonary fibrosis via regulating Smad3 acetylation，Am J Pathol，2013年，183巻6号，1758-1768
Kumar R，Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity，Mol Cancer Ther，2007年，6巻7号，2012-2021

Also Published As

Publication number Publication date
CN110753546B (zh) 2023-11-10
US11166953B2 (en) 2021-11-09
WO2018195084A1 (en) 2018-10-25
US11890283B2 (en) 2024-02-06
US20210121459A1 (en) 2021-04-29
IL270070B1 (en) 2023-05-01
CN110753546A (zh) 2020-02-04
EP3612184A4 (en) 2021-01-20
IL270070B2 (en) 2023-09-01
JP2020516689A (ja) 2020-06-11
CA3060247A1 (en) 2018-10-25
US20240165115A1 (en) 2024-05-23
EP3612184A1 (en) 2020-02-26
IL270070A (enExample) 2019-12-31
EP3612184B1 (en) 2024-06-05
US20220040177A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
US11890283B2 (en) Compounds, compositions and methods of treating or preventing acute lung injury
US7307071B2 (en) RAF-MEK-ERK pathway inhibitors to treat cancer
Nakamura et al. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas
CN103889422A (zh) 治疗胃肠道间质瘤的方法
JP2014522844A (ja) 白血病を治療するための組成物、方法及びキット
Kawakami et al. A novel fusicoccin derivative preferentially targets hypoxic tumor cells and inhibits tumor growth in xenografts
ES2895850T3 (es) Procedimiento de prevención o tratamiento de una enfermedad o afección pulmonar
JP2023502252A (ja) 虚血再灌流傷害および／または肺傷害を処置するための化合物、組成物および方法
Slinko et al. Combined zinc supplementation with proinsulin C-peptide treatment decreases the inflammatory response and mortality in murine polymicrobial sepsis
TW200529813A (en) Cancer therapy
HK40018465B (zh) 治疗或预防急性肺损伤的化合物、组合物和方法
Han et al. Inhibition of protein kinase C-α and activation of ezrin by Lactobacillus acidophilus restore Na+/H+ exchange activity and fluid absorption in db/db mice
HK40018465A (en) Compounds, compositions and methods of treating or preventing acute lung injury
HK40079687A (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
RU2663929C2 (ru) Использование производного соединения тиохромено[2,3-с]хинолин-12-она для лечения немелкоклеточного рака легких
US20130095059A1 (en) Inhaled no donor kmups derivative preventing allergic pulmonary vascular and bronchial inflammation via suppressed cytokines, inos and inflammatory cell counts in asthma model
US9801840B1 (en) Pharmaceutical composition and use thereof
TWI646961B (zh) Dehydrothiamine [2,3- c Use of a quinoline-12-one derivative for the preparation of a medicament for treating non-small cell lung cancer
Roig Exploring the benefits of inhibiting HIF and Notch to overcome resistance to cancer therapy
TW202139992A (zh) 用於癌症治療之醫藥組合
WO2013028866A1 (en) Therapeutic compounds and methods

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210324

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220615

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220714

R150 Certificate of patent or registration of utility model

Ref document number: 7108018

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250